Abstract

We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland. At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.

Cite as

Sheikh, A., Robertson, C. & Taylor, B. 2021, 'BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant', New England Journal of Medicine. https://doi.org/10.1056/NEJMc2113864

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 28 November 2021
Was this page helpful?